VBI Vaccines (NASDAQ:VBIV) issued its earnings results on Friday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02), MarketWatch Earnings reports. The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.24 million. VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%.

VBI Vaccines stock traded down $0.12 during mid-day trading on Friday, hitting $2.05. The stock had a trading volume of 350,317 shares, compared to its average volume of 285,258. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14. VBI Vaccines has a one year low of $1.64 and a one year high of $5.10.

Several research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. ValuEngine raised shares of VBI Vaccines from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Finally, BMO Capital Markets dropped their target price on shares of VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, July 27th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. VBI Vaccines has a consensus rating of “Hold” and a consensus target price of $8.63.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/11/10/vbi-vaccines-vbiv-releases-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Recommended Story: How is an ETF different from a mutual fund?

Earnings History for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.